Literature DB >> 6718733

CT patterns of splenic infarction: a clinical and experimental study.

I Balcar, S E Seltzer, S Davis, S Geller.   

Abstract

The computed tomographic (CT) appearance of splenic infarction has classically been described as peripheral, wedge-shaped, and low in density. Two investigations were designed to determine the appearance of splenic infarcts: (a) a clinical study of 12 patients and (b) a canine experimental model. In the clinical study, two previously undescribed patterns of splenic infarction were found. The classic peripheral, wedge-shaped defects were seen in four patients; multiple, heterogeneous lesions were seen in five; and massive hypodense lesions were noted in three. In three of the nine patients who had both precontrast and postcontrast CT scans, the unenhanced images alone would not have permitted the diagnosis. Contrast enhancement markedly improved infarct visualization in the remaining six. The experimental study of splenic infarction in dogs indicated that CT images can accurately depict the various phases of an infarct as it evolves through stages of congestion, hemorrhage, inflammation, organization, and fibrosis. In addition, a new contrast material--liposome-encapsulated diatrizoate--was used in one of the dogs and was found to produce greater and more sustained differences between normal and abnormal tissue than did conventional contrast material.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6718733     DOI: 10.1148/radiology.151.3.6718733

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  9 in total

1.  Splenic Infarction in Malaria.

Authors:  A N Prasad; A Singh
Journal:  Med J Armed Forces India       Date:  2011-07-21

2.  Liver/spleen scintigraphy for diagnosis of splenic infarction in cirrhotic patients.

Authors:  J K Chin; P A McCormick; A J Hilson; A K Burroughs; N McIntyre
Journal:  Postgrad Med J       Date:  1993-09       Impact factor: 2.401

3.  [Spontaneous splenic rupture after mitral valve replacement for infective endocarditis].

Authors:  T Sugimoto; T Minowa; H Uchino; T Shimanuki; C Nakamura
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-05

4.  Total Splenectomy due to an Unexpected "Complication" after Successful Extended Laparoscopic Partial Decapsulation of a Giant Epidermoid Splenic Cyst: A Case Report.

Authors:  Michail Pitiakoudis; Petros Zezos; Anastasia Oikonomou; Prodromos Laftsidis; Georgios Kouklakis; Constantinos Simopoulos
Journal:  Case Rep Med       Date:  2011-05-31

5.  Splenic infarction and infectious diseases in Korea.

Authors:  Jae Hyoung Im; Moon-Hyun Chung; Hye-Jin Lee; Hea Yoon Kwon; Ji Hyeon Baek; Ji-Hun Jang; Jin-Soo Lee
Journal:  BMC Infect Dis       Date:  2020-12-02       Impact factor: 3.090

6.  Secondary Complications in COVID-19 Patients: A Case Series.

Authors:  Maria Paola Belfiore; Gaetano Maria Russo; Luigi Gallo; Umberto Atripaldi; Stefania Tamburrini; Valentina Caliendo; Luigi Impieri; Maria Teresa Del Canto; Giovanni Ciani; Pasquale Parrella; Maria Luisa Mangoni di Santo Stefano; Antonio Alessandro Heliot Salvia; Fabrizio Urraro; Valerio Nardone; Nicola Coppola; Alfonso Reginelli; Salvatore Cappabianca
Journal:  Tomography       Date:  2022-07-15

Review 7.  Imaging spectrum of abdominal manifestations of COVID-19.

Authors:  Tanvi Vaidya; Avinash Nanivadekar; Rajan Patel
Journal:  World J Radiol       Date:  2021-06-28

8.  Risk assessment and prognostic analysis of patients with splenic infarction in emergency department: a multicenter retrospective study.

Authors:  Chieh-Ching Yen; Chih-Kai Wang; Shou-Yen Chen; Shi-Ying Gao; Hsiang-Yun Lo; Chip-Jin Ng; Chung-Hsien Chaou
Journal:  Sci Rep       Date:  2021-11-02       Impact factor: 4.379

Review 9.  Abdominal and gastrointestinal manifestations in COVID-19 patients: Is imaging useful?

Authors:  Piero Boraschi; Luigi Giugliano; Giuseppe Mercogliano; Francescamaria Donati; Stefania Romano; Emanuele Neri
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.